---
schema_version: "secwatch.filing_event.v1"
accession: "0001798749-24-000042"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2024-07-08T23:59:59+00:00"
generated_at: "2026-05-31T23:06:56.671643+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aerovate Therapeutics halts Phase 3 PAH trial, launches strategic alternatives review with Wedbush

## Summary
- Previously halted enrollment and shut down Phase 3 IMPAHCT trial and long-term extension study.
- Now conducting comprehensive review of strategic alternatives to maximize shareholder value.
- Engaged Wedbush PacGrow as exclusive strategic financial advisor for the review process.
- Alternatives may include acquisition, merger, reverse merger, business combination, or liquidation.
- No timetable set and no assurance any transaction will result from the review.

## SEC filing metadata
- accession: 0001798749-24-000042
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2024-07-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000179874924000042/0001798749-24-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000179874924000042/tmb-20240708x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001798749-24-000042
- JSON: https://secwatch.observer/filing/0001798749-24-000042.json
- Plain text: https://secwatch.observer/filing/0001798749-24-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.